{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:38:25Z","timestamp":1777959505726,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22K06699"],"award-info":[{"award-number":["JP22K06699"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jiac.2023.01.010","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T02:43:02Z","timestamp":1674182582000},"page":"391-400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Population pharmacokinetic model and dosing optimization of vancomycin in hematologic malignancies with neutropenia and augmented renal clearance"],"prefix":"10.1016","volume":"29","author":[{"given":"Tassadit","family":"Belabbas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7009-1727","authenticated-orcid":false,"given":"Takaaki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Egashira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimitaka","family":"Suetsugu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Ieiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2023.01.010_bib1","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2023.01.010_bib2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10156-013-0599-4","article-title":"Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring","volume":"19","author":"Matsumoto","year":"2013","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2023.01.010_bib3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases society of America, the american society of health-system pharmacists, and the society of infectious diseases pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2023.01.010_bib4","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jiac.2023.01.010_bib5","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/imj.12595","article-title":"Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014","volume":"44","author":"Fleming","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.jiac.2023.01.010_bib6","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1086\/383050","article-title":"Management of fever in neutropenic patients with different risks of complications","volume":"39","author":"Klastersky","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2023.01.010_bib7","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: esmo clinical practice guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.jiac.2023.01.010_bib8","article-title":"Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients","volume":"66","author":"Pagano","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2023.01.010_bib9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JOP.18.00269","article-title":"Optimal management of neutropenic fever in patients with cancer","volume":"15","author":"Zimmer","year":"2019","journal-title":"J Pract Oncol"},{"key":"10.1016\/j.jiac.2023.01.010_bib10","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1473-3099(08)70228-7","article-title":"Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia","volume":"8","author":"Lortholary","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2023.01.010_bib11","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1128\/AAC.02340-14","article-title":"Altered pharmacokinetics of piperacillin in febrile neutropenic patients with hematological malignancy","volume":"58","author":"Sime","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2023.01.010_bib12","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/cid\/cis210","article-title":"Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer","volume":"54","author":"Theuretzbacher","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2023.01.010_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11318140-000000000-00000","article-title":"Augmented renal clearance: implications for antibacterial dosing in the critically ill","volume":"49","author":"Udy","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2023.01.010_bib14","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ijantimicag.2011.12.011","article-title":"Augmented renal clearance in septic patients and implications for vancomycin optimisation","volume":"39","author":"Baptista","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2023.01.010_bib15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijantimicag.2014.12.017","article-title":"Augmented renal clearance, low beta-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study","volume":"45","author":"Huttner","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2023.01.010_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/03000605211015573","article-title":"Augmented renal clearance: a retrospective, cohort study of urinary creatinine clearance in critically ill patients in the United Kingdom","volume":"49","author":"Johnston","year":"2021","journal-title":"J Int Med Res"},{"key":"10.1016\/j.jiac.2023.01.010_bib17","doi-asserted-by":"crossref","first-page":"R49","DOI":"10.1186\/cc10013","article-title":"Increased creatinine clearance in polytrauma patients with normal serum creatinine: a retrospective observational study","volume":"15","author":"Minville","year":"2011","journal-title":"Crit Care"},{"key":"10.1016\/j.jiac.2023.01.010_bib18","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijantimicag.2016.12.022","article-title":"Association between augmented renal clearance and clinical outcomes in patients receiving beta-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the bling-ii randomised, placebo-controlled, clinical trial","volume":"49","author":"Udy","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2023.01.010_bib19","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40262-018-0636-7","article-title":"Augmented renal clearance in critically ill patients: a systematic review","volume":"57","author":"Bilbao-Meseguer","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2023.01.010_bib20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/phar.2231","article-title":"Augmented renal clearance","volume":"39","author":"Cook","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2023.01.010_bib21","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/CCM.0000000000000029","article-title":"Augmented renal clearance in the icu: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations","volume":"42","author":"Udy","year":"2014","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jiac.2023.01.010_bib22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13054-015-0750-y","article-title":"Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?","volume":"19","author":"Udy","year":"2015","journal-title":"Crit Care"},{"key":"10.1016\/j.jiac.2023.01.010_bib23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1378\/chest.11-1671","article-title":"Subtherapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations","volume":"142","author":"Udy","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jiac.2023.01.010_bib24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jiph.2019.06.016","article-title":"Population pharmacokinetics of vancomycin in Chinese patients with augmented renal clearance","volume":"13","author":"Chu","year":"2020","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.jiac.2023.01.010_bib25","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1248\/bpb.b19-00652","article-title":"Augmented renal clearance of vancomycin in hematologic malignancy patients","volume":"42","author":"Izumisawa","year":"2019","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jiac.2023.01.010_bib26","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/jcpt.12088","article-title":"Augmented renal clearance--an evolving risk factor to consider during the treatment with vancomycin","volume":"38","author":"Minkute","year":"2013","journal-title":"J Clin Pharm Therapeut"},{"key":"10.1016\/j.jiac.2023.01.010_bib27","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00228-019-02657-6","article-title":"The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults","volume":"75","author":"Bury","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2023.01.010_bib28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cca.2016.12.021","article-title":"Neutropenia is independently associated with sub-therapeutic serum concentration of vancomycin","volume":"465","author":"Choi","year":"2017","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jiac.2023.01.010_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112008","article-title":"Vancomycin dosing in neutropenic patients","volume":"9","author":"Haeseker","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2023.01.010_bib30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.jiac.2023.01.010_bib31","author":"Health Udo"},{"key":"10.1016\/j.jiac.2023.01.010_bib32","series-title":"Architect i vancomycin","year":"2008"},{"key":"10.1016\/j.jiac.2023.01.010_bib33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"key":"10.1016\/j.jiac.2023.01.010_bib34","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/FTD.0000000000000346","article-title":"Augmented renal clearance in patients with febrile neutropenia is associated with increased risk for subtherapeutic concentrations of vancomycin","volume":"38","author":"Hirai","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jiac.2023.01.010_bib35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cytogfr.2018.08.004","article-title":"The cytokine network in acute myeloid leukemia (aml): a focus on pro- and anti-inflammatory mediators","volume":"43","author":"Binder","year":"2018","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jiac.2023.01.010_bib36","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1016\/j.celrep.2017.03.018","article-title":"Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia","volume":"18","author":"Carey","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.jiac.2023.01.010_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.623952","article-title":"Clinical implications of inflammation in acute myeloid leukemia","volume":"11","author":"Recher","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jiac.2023.01.010_bib38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40560-016-0148-1","article-title":"Sepsis-induced myocardial dysfunction: pathophysiology and management","volume":"4","author":"Kakihana","year":"2016","journal-title":"J Intensive Care"},{"key":"10.1016\/j.jiac.2023.01.010_bib39","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/jcph.1106","article-title":"Population pharmacokinetics of vancomycin in patients undergoing allogeneic hematopoietic stem-cell transplantation","volume":"58","author":"Okada","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2023.01.010_bib40","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1128\/AAC.49.12.4934-4941.2005","article-title":"Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies","volume":"49","author":"Buelga","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2023.01.010_bib41","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1128\/AAC.01708-10","article-title":"Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens","volume":"55","author":"Roberts","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2023.01.010_bib42","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00134-006-0470-5","article-title":"Pharmacokinetic\/pharmacodynamic analysis of vancomycin in ICU patients","volume":"33","author":"Del Mar Fernandez de Gatta Garcia","year":"2007","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jiac.2023.01.010_bib43","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated gfr from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X23000181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X23000181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:05:24Z","timestamp":1761159924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X23000181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1341321X23000181"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2023.01.010","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetic model and dosing optimization of vancomycin in hematologic malignancies with neutropenia and augmented renal clearance","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2023.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}